Investigative radiology
-
Investigative radiology · Aug 1992
Multicenter Study Clinical TrialPhase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
The safety and efficacy of a new, low-osmolal magnetic resonance imaging contrast medium, gadoteridol injection, were evaluated in a phase II, open-label study at doses ranging from 0.05 to 0.30 mmol/kg. ⋯ Overall, enhanced images provided more diagnostic information and facilitated detection of more lesions than precontrast images. Gadoteridol injection at doses up to 0.3 mmol/kg is a safe and effective magnetic resonance imaging contrast agent for use in patients with intracranial tumors.